Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis

Pharmaceutical Research

Volumn 27, Issue 6, 2010, Pages 1080-1091

  Bishayee, Anupam ^a   Waghray, Abhijeet ^a   Barnes, Kendra F ^a   Mbimba, Thomas ^a   Bhatia, Deepak ^a   Chatterjee, Malay ^b   Darvesh, Altaf S ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Chemoprevention; Hepatocarcinogenesis; Inflammation; NF B; Resveratrol

Indexed keywords

CYCLOOXYGENASE 2; DIETHYLNITROSAMINE; HEAT SHOCK PROTEIN 70; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RESVERATROL; TRANSCRIPTION FACTOR RELA;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STABILITY; RAT; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CYCLOOXYGENASE 2; DIETHYLNITROSAMINE; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INFLAMMATION; LIVER; LIVER NEOPLASMS; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

EID: 77953231047     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0144-4     Document Type: Article

References (76)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin. 55 74 105 10.3322/canjclin.55.2.74 15761078
2. M Sherman 2005 Hepatocellular carcinoma: epidemiology, risk factors, and screening Semin Liver Dis. 25 143 54 10.1055/s-2005-871194 15918143 (Pubitemid 40781067)
3. HB El-Serag 2004 Hepatocellular carcinoma: recent trends in the United States Gastroenterology 127 S27 34 10.1053/j.gastro.2004.09.013 15508094 (Pubitemid 39423367)
4. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA, 2009.
5. L Wu Z-Y Tang Y Li 2009 Experimental models of hepatocellular carcinoma: developments and evolution J Cancer Res Clin Oncol. 135 969 81 10.1007/s00432-009-0591-7 19399516
6. K Schütte J Bornschein P Malfertheiner 2009 Hepatocellular carcinoma-epidemiological trends and risk factors Dig Dis. 27 80 92 19546545
7. H Bartsch R Montesano 1984 Relevance of nitrosamines to human cancer Carcinogenesis 5 1381 93 10.1093/carcin/5.11.1381 6386215
8. TW Kensler PA Egner JB Wang YR Zhu BC Zhang PX Lu, et al. 2004 Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas Gastroenterology 127 S310 8 10.1053/j.gastro.2004.09.046 15508099 (Pubitemid 39423401)
9. JM Llovet A Burroughs J Bruix 2003 Hepatocellular carcinoma Lancet 362 1907 17 10.1016/S0140-6736(03)14964-1 14667750 (Pubitemid 37518510)
10. Y Je FAB Schutz TK Choueiri 2009 Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and mata-analysis of clinical trials Lancet Oncol. 10 967 74 10.1016/S1470-2045(09)70222-0 19767240
11. M Okuno S Kojima H Moriwaki 2001 Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives J Gastroenterol Hepatol. 16 1329 35 10.1046/j.1440-1746.2001.02634.x 11851828 (Pubitemid 34107398)
12. MS Yates TW Kensler 2007 Keap1 eye on the target: chemoprevention of liver cancer Acta Pharmacol Sin. 28 1331 42 10.1111/j.1745-7254.2007.00688.x 17723167 (Pubitemid 47366685)
13. C Berasain J Casillo MJ Perugorria MU Latasa J Prieto MA Avila 2009 Inflammation and liver cancer: new molecular links Ann NY Acad Sci. 1155 206 21 10.1111/j.1749-6632.2009.03704.x 19250206
14. M Joo JG Chi L Hyucksang 2005 Expressions of HSP70 and HSP27 in hepatocellular carcinoma J Korean Med Sci. 20 829 34 10.3346/jkms.2005.20.5.829 16224158
15. A Murakami H Ashida J Terao 2008 Multitargeted cancer prevention by quercetin Cancer Lett. 269 315 25 10.1016/j.canlet.2008.03.046 18467024
16. T Wu 2006 Cyclooxygenase-2 in hepatocellular carcinoma Cancer Treat Rev. 32 28 44 10.1016/j.ctrv.2005.10.004 16337744 (Pubitemid 43159775)
17. L Giannitrapani S Ingrao M Soresi A Maria Florena E La Spada L Sandonato, et al. 2009 Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma Ann NY Acad Sci. 1155 293 9 10.1111/j.1749-6632.2009. 03698.x 19250220
18. Y Yildirim O Ozyilkan B Bilezikci Z Akcali M Haberal 2008 Lack of influence of cyclooxygenase-2 expression in hepatocellular carcinomas on patient survival Asian Pac J Cancer Prev. 9 295 8 18712978
19. M Karin 2008 The IκB kinase-a bridge between inflammation and cancer Cell Res. 18 334 432 10.1038/cr.2008.30 18301380 (Pubitemid 351333897)
20. P Muriel 2009 NF-κB in liver diseases: a target for drug therapy J Appl Toxicol. 29 91 100 10.1002/jat.1393 18937212
21. AM Elsharkawy DA Mann 2007 Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis Hepatology 46 590 7 10.1002/hep.21802 17661407 (Pubitemid 47344795)
22. BB Aggarwal RV Vijayalekshmi B Sung 2009 Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe Clin Cancer Res. 15 425 30 10.1158/1078-0432.CCR-08-0149 19147746
23. BB Aggarwal S Shishodia 2006 Molecular targets of dietary agents for prevention and therapy of cancer Biochem Pharmacol. 71 1397 421 10.1016/j.bcp.2006.02.009 16563357
24. R Naithani LC Huma RM Moriarty DL McCormick RG Mehta 2008 Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials Curr Med Chem. 15 1044 71 10.2174/092986708784221403 18473802 (Pubitemid 352005717)
25. I Rahman SK Biswas PA Kirkham 2005 Regulation of inflammation and redox signaling by dietary polyphenols Biochem Pharmacol. 72 1439 52 10.1016/j.bcp.2006.07.004
26. YS Kim MR Young G Bobe NH Colbum JA Milner 2009 Bioactive food components, inflammatory targets, and cancer prevention Cancer Prev Res. 2 200 8 10.1158/1940-6207.CAPR-08-0141
27. CD Mann CP Neal G Garcea MM Manson AR Dennison DP Berry 2009 Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis Eur J Cancer Prev. 18 13 25 10.1097/CEJ.0b013e3282f0c090 19077560
28. R Vidavalur H Otani PK Singal N Maulik 2006 Significance of wine and resveratrol in cardiovascular disease: French paradox revisited Exp Clin Cardiol. 11 217 25 18651034
29. M Shakibaei KB Harikumar BB Aggarwal 2009 Resveratrol addiction: to die or not to die Mol Nutr Food Res. 53 115 28 10.1002/mnfr.200800148 19072742
30. M Athar JH Back L Kopelovich DR Bickers AL Kim 2009 Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms Arch Biochem Biophys. 486 95 102 10.1016/j.abb.2009.01.018 19514131
31. BB Aggarwal A Bhardwaj RS Aggarwal NP Seeram S Shishodia Y Takada 2004 Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies Anticancer Res. 24 2783 840 15517885
32. JK Kundu Y-J Surh 2008 Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives Cancer Lett. 269 243 61 10.1016/j.canlet.2008.03.057 18550275
33. A Bishayee 2009 Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials Cancer Prev Res. 2 409 18 10.1158/1940-6207. CAPR-08-0160
34. A Bishayee T Politis AS Darvesh 2010 Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma Cancer Treat Rev. 36 43 53 10.1016/j.ctrv.2009.10.002 19910122
35. A Bishayee N Dhir 2009 Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis Chem-Biol Interact. 179 131 44 10.1016/j.cbi.2008.11.015 19073162
36. E Farber DS Sarma 1987 Hepatocarcinogenesis: a dynamic cellular perspective Lab Invest. 56 4 22 3025514
37. S Das DK Das 2007 Anti-inflammatory responses of resveratrol Inflamm Allergy Drug Target. 6 168 73 10.2174/187152807781696464 (Pubitemid 47455785)
38. JD Dignam RM Lebovitz RG Roeder 1983 Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei Nucleic Acid Res. 11 1475 89 10.1093/nar/11.5.1475 6828386
39. RI Morimoto 1993 Cells in stress: transcriptional activation of heat shock genes Science 259 1409 10 10.1126/science.8451637 8451637
40. C Jolly RI Morimoto 2000 Role of the heat shock response and molecular chaperones in oncogenesis and cell death J Natl Cancer Inst. 92 1564 72 10.1093/jnci/92.19.1564 11018092
41. SO Lim SG Park J-H Yoo YM Park H-J Kim K-T Jang, et al. 2005 Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules World J Gastroenterol. 11 2072 9 15810071
42. S Yoshida S Hazama K Tokuno K Sakamoto M Takashima T Tamesa, et al. 2009 Concomitant overexpression of heat-shock protein 70 and HLA class-I in hepatitis C virus-related hepatocellular carcinoma Anticancer Res. 29 539 44 19331200
43. M Chuma M Sakamoto K Yamazaki T Ohta M Ohki S Hirohashi 2003 Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma Hepatology 37 198 207 10.1053/jhep.2003.50022 12500205 (Pubitemid 36042161)
44. BI Carr TH Huang CH Buzin K Itakura 1986 Induction of heat shock gene expression without heat shock by hepatocarcinogenesis Cancer Res. 46 5106 11 3756868
45. L Tacchini L Schiaffonati E Rappocciolo G Cairo A Bernelli-Zazzera 1989 Expression pattern of the genes for the different members of the heat-shock protein 70 family, ornithine decarboxylase, and c-Ha-ras during the early stages of hepatocarcinogenesis Mol Carcinog. 2 233 6 10.1002/mc.2940020502 2690852 (Pubitemid 20033366)
46. T Takami P Kaposi-Novak K Uchida LE Gomez-Quiroz EA Conner VM Factor, et al. 2007 Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine-induced hepatocarcinogenesis Cancer Res. 67 9844 51 10.1158/0008-5472.CAN-07-1905 17942915 (Pubitemid 47621232)
47. V Cardile C Scifo A Russo M Falsaperla G Morgia M Motta, et al. 2003 Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer Anticancer Res. 23 4921 6 14981946
48. PK Chakraborty SB Mustafi S Ganguly M Chatterjee S Raha 2008 Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70 Cancer Sci. 99 1109 16 10.1111/j.1349-7006.2008.00809.x 18429957 (Pubitemid 351676621)
49. M Sengottuvelan K Deeptha N Nalini 2009 Influences of dietary resveratrol on early and late molecular markers of 1, 2-dimethylhydrazine-induced colon carcinogenesis Nutrition 25 1169 76 10.1016/j.nut.2009.03.009 19818280
50. T Hla K Nielson 1992 Human cyclooxygenase-2 cDNA Proc Natl Acad Sci USA 89 7384 8 10.1073/pnas.89.16.7384 1380156
51. E Fosselin 2000 Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia Crit Rev Clin Lab Sci. 37 431 502 10.1080/10408360091174286
52. SM Prescott FA Fitzpatrick 2000 Cyclooxygenase-2 and carcinogenesis Biochim Biophys Acta 1470 M69 78 10722929
53. H Koga S Sakisaka M Ohishi T Kawaguchi E Taniguchi K Sasatomi, et al. 1999 Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation Hepatology 29 688 96 10.1002/hep.510290355 10051469
54. YK Sung SY Hwang JO Kim HI Bae JC Kim MK Kim 2004 The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis Mol Cells 17 35 8 15055524
55. KQ Hu 2002 Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors J Lab Clin Med. 139 234 43 10.1067/mlc.2002.122281 12024111 (Pubitemid 34557358)
56. H Koga 2003 Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer 98 661 7 10.1002/cncr.11576 12910508 (Pubitemid 36959260)
57. G Ramakrishnan CM Elinos-Báez S Jagan TA Augustine S Kamaraj P Anandakumar, et al. 2008 Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma Mol Cell Biochem. 313 53 61 10.1007/s11010-008-9741-5 18373278
58. V Sivaramakrishnan S Niranjali Devaraj 2009 Morin regulates the expression of NF-kappaB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma Chem-Biol Interact 180 353 9 10.1016/j.cbi.2009.02.004 19539802
59. Bishayee A, Barnes KF, Bhatia D, Darvesh AS, Carroll RT. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine- initiated rat hepatocarcinogenesis. Cancer Prev Res. 2010;in press.
60. KL Khanduja A Bhardwai G Kaushik 2004 Resveratrol inhibits N-nitrosodiethylamine-induced ornithine decarboxylase and cyclooxygenase in mice J Nutr Sci Vitaminol. 50 61 5 15228220
61. M Tsujii RN DuBois 1995 Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 Cell 83 493 501 10.1016/0092-8674(95)90127-2 8521479
62. TA Zycova F Zhu X Zhai W-Y Ma SP Ermakova KW Lee, et al. 2008 Resveratrol directly targets COX-2 to inhibit carcinogenesis Mol Carcinog. 47 797 805 10.1002/mc.20437
63. M Cervello G Montalto 2006 Cyclooxygenase in hepatocellular carcinoma World J Gastroenterol. 12 5113 21 16937518
64. Luther DJ, Ohanyan V, Shamhart PE, Hodnichak CM, Sisakian H, Booth TD, et al. Chemopreventive doses of resveratrol do not affect cardiac function in a rodent model of hepatocellular carcinoma. Invest New Drugs. 2010; in press. doi: 10.1007/s10637-009-9332-7.
65. M Karin A Lin 2002 NF-kappaB at the crossroads of life and death Nat Immunol. 3 221 7 10.1038/ni0302-221 11875461 (Pubitemid 34213423)
66. MA Rahman DK Dhar E Yamaguchi S Maruyama T Sato H Hayashi, et al. 2001 Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases Clin Cancer Res. 7 1325 32 11350902
67. DF Calvisi F Pinna S Ladu R Pellegrino MR Muroni MM Simile, et al. 2008 Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease Carcinogenesis 29 1639 47 10.1093/carcin/bgn155 18579559
68. R Tazawa XM Xu KK Wu LH Wang 1994 Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene Biochem Biophys Res Commun. 203 190 9 10.1006/bbrc.1994.2167 8074655 (Pubitemid 24281079)
69. QW Xie Y Kashiwabara C Nathan 1994 Role of transcription factor NF-B/Rel in induction of nitric oxide synthase J Biol Chem. 269 4705 8 7508926
70. S Ueno D Aoki F Kubo K Hiwatashi K Matsushita T Oyama, et al. 2005 Roxithromyc inhibits constitutive activation of nuclear factor κB by diminishing oxidative stress in a rat model of hepatocellular carcinoma Clin Cancer Res. 11 5645 50 10.1158/1078-0432.CCR-05-0652 16061884 (Pubitemid 41060844)
71. Z Yang S Yang BJ Misner R Chiu F Liu FL Meyskens 2008 Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol Mol Cancer Ther. 7 3751 60 10.1158/1535-7163.MCT-08-0562 19074850
72. O-H Kang H-J Jang H-S Chae Y-C Oh J-G Choi Y-S Lee, et al. 2009 Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-κB and MAPK Pharmacol Res. 59 330 7 10.1016/j.phrs.2009.01.009 19416633
73. M Cichocki J Paluszczak H Szaefer A Piechowiak AM Rimando W Baer-Dubowska 2008 Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFκB, AP-1, COX-2, and iNOS in mouse epidermis Mol Nutr Food Res. 52 S62 70 10.1002/mnfr.200700395 18551458 (Pubitemid 351211803)
74. 4 treatment in rats J Appl Toxicol. 28 35 43 10.1002/jat.1249 17429801
75. M Holmes-McNary AS Baldwin Jr 2000 Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase Cancer Res. 60 3477 83 10910059
76. KT Howitz KJ Bitterman HY Cohen DW Lamming S Lavu JG Wood, et al. 2003 Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 191 6 10.1038/nature01960 12939617 (Pubitemid 37150899)